. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------|-------------------------------| | For the | transition per ...

Contact: Investor Relations DaVita Inc. ir@davita.com DaVita Inc. 3rd Quarter 2024 Results Denver, Colorado, October 29, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of ou ...

DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quart ...

DaVita Inc. (DVA) is scheduled to report third-quarter 2024 results on Oct. 29, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of $2.59 surpassed the Zacks Consensus Estimate by 4.9%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 24.2%, on average.For third-quarter 2024, the Zacks Consensus Estimate for revenues is pegged at $3.22 billion, implying an improvement of 3.2 ...

DENVER and SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a leading innovator in kidney care research and wholly owned subsidiary of DaVita Inc., will present the results of five innovative research projects at the American Society of Nephrology (ASN)'s annual Kidney Week meeting, which is currently underway in San Diego, CA. With a focus on improving racial equity in transplantation and key measures of clinical quality such as hospitalizations, DCR works to tackle pressing issues ...

In the latest market close, DaVita HealthCare (DVA) reached $163.16, with a +1% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.05%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.18%.The kidney dialysis provider's shares have seen a decrease of 0.02% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.76%.Investors will be eagerly watching for the perfo ...

Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patientsDENVER, Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes ...

DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. Jess HergenreterJess Hergenreter "Our incre ...

DaVita HealthCare (DVA) ended the recent trading session at $164.82, demonstrating a +0.15% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.47%. At the same time, the Dow added 0.79%, and the tech-heavy Nasdaq gained 0.28%. Shares of the kidney dialysis provider witnessed a gain of 0.21% over the previous month, beating the performance of the Medical sector with its loss of 4.27% and underperforming the S&P 500's gain of 3.48%. Market participants will be closely ...

Shares of DaVita (DVA) have risen 115.5% in the past year, outperforming the Zacks Medical - Outpatient and Home Healthcare industry's growth of 37.8% and the broader Zacks Medical sector's return of 12.3%. The strong bull run in the DVA stock was primarily due to rising demand for its dialysis services, following the disruption of demand amid COVID-19. The upward trend is expected to persist through the remainder of 2024 and beyond, driven by increasing demand for dialysis services due to a growing number ...